Trial ID or NCT#

NCT00371189

Status

NOT RECRUITING

Purpose

Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria. Participants will include 72 healthy adults, ages18 to 45, enrolled at Vanderbilt University Medical Center and Stanford University. Volunteers will receive 3 doses of either the malaria vaccine or placebo (contains no vaccine) by injection into a muscle at 0, 1 and 6 months. Investigators will evaluate how the body responds to increasing dosage strengths of the vaccine. Study procedures include physical exam, multiple blood draws, and completion of a memory aid (diary). Each participant will be actively involved in the study for about 12 months. Then, an annual phone call will be made to check for any serious illness events for a period of 5 years.

Official Title

A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age

Eligibility Criteria

Ages Eligible for Study: 18 Years to 45 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes

Investigator(s)

Cornelia L. Dekker, M.D.
Professor (Research) of Pediatrics (Infectious Diseases), Emerita
Dora Ho
Infectious disease doctor
Clinical Associate Professor, Medicine - Infectious Diseases

Contact us to find out if this trial is right for you.

CONTACT

Stanford-LPCH Vaccine Program
(650) 498-7284